High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19 : first results of ReumaCoV Brasil registry

Objectives To evaluate risk factors associated with unfavourable outcomes: emergency care, hospitalisation, admission to intensive care unit (ICU), mechanical ventilation and death in patients with immune-mediated rheumatic disease (IMRD) and COVID-19. Methods Analysis of the first 8 weeks of obser...

Full description

Main Authors: Marques, Claudia Diniz Lopes, Kakehasi, Adriana Maria, Pinheiro, Marcelo Medeiros, Mota, Licia Maria Henrique, Albuquerque, Cleandro Pires, Silva, Carolina Rocha, Santos, Gabriela Porfirio Jardim, Reis Neto, Edgard Torres, Matos, Pedro, Devide, Guilherme, Dantas, Andrea, Giorgi, Rina Dalva, Omura, Felipe, Marinho, Adriana de Oliveira, Valadares, Lilian David Azevedo, Melo, Ana Karla G., Ribeiro, Francinne Machado, Ferreira, Gilda Aparecida, Santos, Flavia Patricia de Sena, Ribeiro, Sandra Lucia Euzebio, Andrade, Nicole Pamplona Bueno, Yazbek, Michel Alexandre, Souza, Viviane Angelina de, Paiva, Eduardo S., Azevedo, Valderilio Feijo, Freitas, Ana Beatriz Santos Bacchiega de, Provenza, José Roberto, Toledo, Ricardo Acayaba de, Fontenelle, Sheilla, Carneiro, Sueli, Xavier, Ricardo, Pileggi, Gecilmara Cristina Salviato, Reis, Ana Paula Monteiro Gomides
Format: Artigo
Language: Inglês
Published: BMJ Journals 2021
Subjects:
Online Access: https://repositorio.unb.br/handle/10482/40399
http://dx.doi.org/10.1136/rmdopen-2020-001461
https://orcid.org/0000-0002-3333-2621
Tags: Add Tag
No Tags, Be the first to tag this record!
id ir-10482-40399
recordtype dspace
spelling ir-10482-403992021-05-14T16:52:40Z High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19 : first results of ReumaCoV Brasil registry Marques, Claudia Diniz Lopes Kakehasi, Adriana Maria Pinheiro, Marcelo Medeiros Mota, Licia Maria Henrique Albuquerque, Cleandro Pires Silva, Carolina Rocha Santos, Gabriela Porfirio Jardim Reis Neto, Edgard Torres Matos, Pedro Devide, Guilherme Dantas, Andrea Giorgi, Rina Dalva Omura, Felipe Marinho, Adriana de Oliveira Valadares, Lilian David Azevedo Melo, Ana Karla G. Ribeiro, Francinne Machado Ferreira, Gilda Aparecida Santos, Flavia Patricia de Sena Ribeiro, Sandra Lucia Euzebio Andrade, Nicole Pamplona Bueno Yazbek, Michel Alexandre Souza, Viviane Angelina de Paiva, Eduardo S. Azevedo, Valderilio Feijo Freitas, Ana Beatriz Santos Bacchiega de Provenza, José Roberto Toledo, Ricardo Acayaba de Fontenelle, Sheilla Carneiro, Sueli Xavier, Ricardo Pileggi, Gecilmara Cristina Salviato Reis, Ana Paula Monteiro Gomides Pacientes Reumatismo Covid-19 Objectives To evaluate risk factors associated with unfavourable outcomes: emergency care, hospitalisation, admission to intensive care unit (ICU), mechanical ventilation and death in patients with immune-mediated rheumatic disease (IMRD) and COVID-19. Methods Analysis of the first 8 weeks of observational multicentre prospective cohort study (ReumaCoV Brasil register). Patients with IMRD and COVID-19 according to the Ministry of Health criteria were classified as eligible for the study. Results 334 participants were enrolled, a majority of them women, with a median age of 45 years; systemic lupus erythematosus (32.9%) was the most frequent IMRD. Emergency care was required in 160 patients, 33.0% were hospitalised, 15.0% were admitted to the ICU and 10.5% underwent mechanical ventilation; 28 patients (8.4%) died. In the multivariate adjustment model for emergency care, diabetes (prevalence ratio, PR 1.38; 95% CI 1.11 to 1.73; p=0.004), kidney disease (PR 1.36; 95% CI 1.05 to 1.77; p=0.020), oral glucocorticoids (GC) (PR 1.49; 95% CI 1.21 to 1.85; p<0.001) and pulse therapy with methylprednisolone (PR 1.38; 95% CI 1.14 to 1.67; p=0.001) remained significant; for hospitalisation, age >50 years (PR 1.89; 95% CI 1.26 to 2.85; p=0.002), no use of tumour necrosis factor inhibitor (TNFi) (PR 2.51;95% CI 1.16 to 5.45; p=0.004) and methylprednisolone pulse therapy (PR 2.50; 95% CI 1.59 to 3.92; p<0.001); for ICU admission, oral GC (PR 2.24; 95% CI 1.36 to 3.71; p<0.001) and pulse therapy with methylprednisolone (PR 1.65; 95% CI 1.00 to 2.68; p<0.043); the two variables associated with death were pulse therapy with methylprednisolone or cyclophosphamide (PR 2.86; 95% CI 1.59 to 5.14; p<0.018). Conclusions Age >50 years and immunosuppression with GC and cyclophosphamide were associated with unfavourable outcomes of COVID-19. Treatment with TNFi may have been protective, perhaps leading to the COVID-19 inflammatory process. 2021-03-30T17:56:11Z 2021-03-30T17:56:11Z 2021 Artigo MARQUES, Claudia Diniz Lopes et al. High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry. RMD Open, v. 7, n. 1, e001461, 2021. DOI: http://dx.doi.org/10.1136/rmdopen-2020-001461. Disponível em: https://rmdopen.bmj.com/content/7/1/e001461. Acesso em: 31 mar. 2021. https://repositorio.unb.br/handle/10482/40399 http://dx.doi.org/10.1136/rmdopen-2020-001461 https://orcid.org/0000-0002-3333-2621 Inglês Acesso Aberto Open access - This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work noncommercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/ licenses/by-nc/4.0/. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. application/pdf BMJ Journals
institution REPOSITORIO UNB
collection REPOSITORIO UNB
language Inglês
topic Pacientes
Reumatismo
Covid-19
spellingShingle Pacientes
Reumatismo
Covid-19
Marques, Claudia Diniz Lopes
Kakehasi, Adriana Maria
Pinheiro, Marcelo Medeiros
Mota, Licia Maria Henrique
Albuquerque, Cleandro Pires
Silva, Carolina Rocha
Santos, Gabriela Porfirio Jardim
Reis Neto, Edgard Torres
Matos, Pedro
Devide, Guilherme
Dantas, Andrea
Giorgi, Rina Dalva
Omura, Felipe
Marinho, Adriana de Oliveira
Valadares, Lilian David Azevedo
Melo, Ana Karla G.
Ribeiro, Francinne Machado
Ferreira, Gilda Aparecida
Santos, Flavia Patricia de Sena
Ribeiro, Sandra Lucia Euzebio
Andrade, Nicole Pamplona Bueno
Yazbek, Michel Alexandre
Souza, Viviane Angelina de
Paiva, Eduardo S.
Azevedo, Valderilio Feijo
Freitas, Ana Beatriz Santos Bacchiega de
Provenza, José Roberto
Toledo, Ricardo Acayaba de
Fontenelle, Sheilla
Carneiro, Sueli
Xavier, Ricardo
Pileggi, Gecilmara Cristina Salviato
Reis, Ana Paula Monteiro Gomides
High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19 : first results of ReumaCoV Brasil registry
description Objectives To evaluate risk factors associated with unfavourable outcomes: emergency care, hospitalisation, admission to intensive care unit (ICU), mechanical ventilation and death in patients with immune-mediated rheumatic disease (IMRD) and COVID-19. Methods Analysis of the first 8 weeks of observational multicentre prospective cohort study (ReumaCoV Brasil register). Patients with IMRD and COVID-19 according to the Ministry of Health criteria were classified as eligible for the study. Results 334 participants were enrolled, a majority of them women, with a median age of 45 years; systemic lupus erythematosus (32.9%) was the most frequent IMRD. Emergency care was required in 160 patients, 33.0% were hospitalised, 15.0% were admitted to the ICU and 10.5% underwent mechanical ventilation; 28 patients (8.4%) died. In the multivariate adjustment model for emergency care, diabetes (prevalence ratio, PR 1.38; 95% CI 1.11 to 1.73; p=0.004), kidney disease (PR 1.36; 95% CI 1.05 to 1.77; p=0.020), oral glucocorticoids (GC) (PR 1.49; 95% CI 1.21 to 1.85; p<0.001) and pulse therapy with methylprednisolone (PR 1.38; 95% CI 1.14 to 1.67; p=0.001) remained significant; for hospitalisation, age >50 years (PR 1.89; 95% CI 1.26 to 2.85; p=0.002), no use of tumour necrosis factor inhibitor (TNFi) (PR 2.51;95% CI 1.16 to 5.45; p=0.004) and methylprednisolone pulse therapy (PR 2.50; 95% CI 1.59 to 3.92; p<0.001); for ICU admission, oral GC (PR 2.24; 95% CI 1.36 to 3.71; p<0.001) and pulse therapy with methylprednisolone (PR 1.65; 95% CI 1.00 to 2.68; p<0.043); the two variables associated with death were pulse therapy with methylprednisolone or cyclophosphamide (PR 2.86; 95% CI 1.59 to 5.14; p<0.018). Conclusions Age >50 years and immunosuppression with GC and cyclophosphamide were associated with unfavourable outcomes of COVID-19. Treatment with TNFi may have been protective, perhaps leading to the COVID-19 inflammatory process.
format Artigo
author Marques, Claudia Diniz Lopes
Kakehasi, Adriana Maria
Pinheiro, Marcelo Medeiros
Mota, Licia Maria Henrique
Albuquerque, Cleandro Pires
Silva, Carolina Rocha
Santos, Gabriela Porfirio Jardim
Reis Neto, Edgard Torres
Matos, Pedro
Devide, Guilherme
Dantas, Andrea
Giorgi, Rina Dalva
Omura, Felipe
Marinho, Adriana de Oliveira
Valadares, Lilian David Azevedo
Melo, Ana Karla G.
Ribeiro, Francinne Machado
Ferreira, Gilda Aparecida
Santos, Flavia Patricia de Sena
Ribeiro, Sandra Lucia Euzebio
Andrade, Nicole Pamplona Bueno
Yazbek, Michel Alexandre
Souza, Viviane Angelina de
Paiva, Eduardo S.
Azevedo, Valderilio Feijo
Freitas, Ana Beatriz Santos Bacchiega de
Provenza, José Roberto
Toledo, Ricardo Acayaba de
Fontenelle, Sheilla
Carneiro, Sueli
Xavier, Ricardo
Pileggi, Gecilmara Cristina Salviato
Reis, Ana Paula Monteiro Gomides
author_sort Marques, Claudia Diniz Lopes
title High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19 : first results of ReumaCoV Brasil registry
title_short High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19 : first results of ReumaCoV Brasil registry
title_full High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19 : first results of ReumaCoV Brasil registry
title_fullStr High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19 : first results of ReumaCoV Brasil registry
title_full_unstemmed High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19 : first results of ReumaCoV Brasil registry
title_sort high levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and covid-19 : first results of reumacov brasil registry
publisher BMJ Journals
publishDate 2021
url https://repositorio.unb.br/handle/10482/40399
http://dx.doi.org/10.1136/rmdopen-2020-001461
https://orcid.org/0000-0002-3333-2621
_version_ 1710449497587318784
score 13.657419